Internet searches on weight-loss medications have increased 25-fold since the launch of GLP-1 drugs
Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City…
Read the full articleYou might also wanna read
Nearly one in 10 Britons use or want weight-loss medication
The prevalence of GLP-1 receptor agonists for weight management in Great Britain highlights public interest and concerns over safety and pre
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
Stronger safeguards are needed to ensure independent and transparent recommendations Glucagon-like peptide-1 (GLP-1) receptor agonists and r
bmj.com·27d agoGLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer
The post GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer appeared first on European Medical Journal .
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
New GLP-1 Drug Promotes Weight Loss in Obesity
A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to an 11 percent reduction in body
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
Conditions : Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight Interventions : Drug: GLP-1 Receptor Agonists; Drug: DPP-4 In
Comments
Sign in to join the conversation.
No comments yet. Be the first.